|
CONNECT WITH US
|
|
||||||||||||||
Within the relatively short time that ipilimumab and vemurafenib have been commercially available, phase II data for the investigational agents nivolumab and MK-3475, for the combination of dabrafenib and trametinib, and for adoptive cell therapy strongly suggest even further improvements in treatment outcomes.
We describe areas where major inroads were initially achieved by targeting angiogenesis and by unraveling
pathways in the heterogeneous tumors of mesenchymal origin—spurred by the identification of c-Kit–activating
mutations in GIST and the regressions that ensued when tumors harboring these mutations were exposed to the
tyrosine kinase inhibitor imatinib (Gleevec).
The management of in-transit metastases is challenging, since the treatments and extent of disease vary greatly based on the number, depth, location, and distribution of lesions, and on their biological behavior.
With the potential for therapeutic durability and a small chance of cure, surgical resection may offer improved survival compared to other therapeutic modalities. This review summarizes the existing literature that addresses the topic of metastasectomy in patients with melanoma and breast cancer.
This marks the first randomized clinical trial reporting an overall survival benefit using immune modulation in metastatic melanoma. Along with its therapeutic benefits, ipilimumab presents unique challenges to clinicians.
A 3-year-old child is evaluated for leukocoria (white pupil) of the right eye. Ophthalmic evaluation revealed the presence of a mass behind the lens. Surgical removal of the right eye was performed. What is your Diagnosis?
A 38-year-old man consults for a small subcutaneous nodule of approximately 2 cm in diameter. Surgical excision of the tumor nodule is performed. What is your diagnosis?
A 67-year-old African American female presented with an approximately 18-month history of a solitary, asymptomatic lesion on the right leg. This patient most likely has what tumor on her leg?
In this podcast we discuss the recent advances in the management and treatment of metastatic melanoma with Jeffrey Sosman, MD, medical oncologist and director of the Melanoma and Tumor Immunotherapy Program at the Vanderbilt-Ingram Cancer Center in Nashville, Tennessee.
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources
© 1996 - 2013 UBM Medica LLC, a
UBM company
Privacy Statement -
Terms of Service -
Advertising Information -
Editorial Policy Statement -
UBM Medica Network Privacy Policy